Ibrance (Palbociclib)

Ibrance (palbociclib) is used in hormone‑driven breast cancer pathways to inhibit tumor growth.

• Hormone receptor‑positive, HER2‑negative advanced breast cancer (first‑line): combined with an aromatase inhibitor to prolong progression‑free survival.
• Hormone receptor‑positive, HER2‑negative advanced breast cancer (post‑progression): combined with fulvestrant to delay disease progression.
• Hormone receptor‑positive, HER2‑negative metastatic breast cancer (in combination therapy): used with endocrine agents to improve overall disease control.

• Palbociclib selectively inhibits cyclin‑dependent kinases 4 and 6, key regulators of the transition from the G1 to the S phase of the cell cycle. By blocking CDK4/6 activity, the drug prevents phosphorylation of the retinoblastoma (Rb) protein, maintaining Rb in its active, growth‑suppressive state and thereby halting proliferation of estrogen‑driven breast cancer cells. The inhibition is dose‑dependent and reversible, allowing normal cells to resume division when drug levels fall.

Palbociclib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: decreased neutrophil count, often asymptomatic.
• Leukopenia: reduced white blood cell count.
• Anemia: lowered red blood cell levels causing fatigue.
• Nausea: mild to moderate gastrointestinal upset.
• Fatigue: general tiredness and reduced energy.
• Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils, requiring urgent care.
• Severe infections: pneumonia or sepsis due to immune suppression.
• Pulmonary embolism: blood clot in lung arteries, a medical emergency.
• Elevated liver enzymes: significant increase in ALT/AST indicating hepatic stress.
• Thrombocytopenia: markedly low platelet count, increasing bleeding risk.

Before initiating therapy with Ibrance, clinicians should consider several safety measures to minimize risks.

• Monitor blood counts: perform regular CBCs to detect neutropenia or anemia.
• Assess liver function: evaluate hepatic enzymes and adjust if moderate impairment.
• Review concomitant medications: avoid strong CYP3A4 inhibitors that may raise palbociclib exposure.
• Counsel on contraception: potential fetal toxicity requires effective birth control during treatment and for several weeks after.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Palbociclib interacts with several drugs that can alter its plasma concentration or additive toxicities.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase palbociclib exposure and risk of neutropenia.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce exposure, potentially decreasing efficacy.
• Concurrent myelosuppressive agents: additive bone‑marrow suppression may be severe.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise drug levels; monitor blood counts.
• Antacids containing aluminum or magnesium: could affect absorption; separate administration by at least 2 hours.
• Warfarin: potential for altered anticoagulant effect; check INR regularly.